Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data ...

However, a key issue that has emerged is the significant loss of lean muscle mass associated ... but frankly from FDA's labeling approach, they really don't define it by age short of gene therapy, ...

We intend to deliver on these value drivers using a more lean corporate infrastructure built on the core ... which we intend to work with the FDA to improve for future seasons. We are managing through ...

Following discussions with the FDA, we've submitted a biologics license application for approval in later-line EGFR-mutated non ... to promote fat-specific weight loss while preserving lean muscle ...

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time, I would like to welcome everyone to ...

Thank you for standing by. My name is John, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings third-quarter results conference call.

In today’s fast-paced world, maintaining sexual vitality can be a challenge for many men. Factors such as stress, aging, and ...

Finding support and a community to lean on can be so important ... She started by talking about the accelerated pathway of ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

"Starting with ART26.12, our promising Fatty Acid Binding Protein 5 (FABP5) inhibitor drug candidate, we received FDA ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada ...